ProfileGDS5678 / 1456094_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 47% 47% 47% 48% 46% 47% 45% 48% 57% 47% 47% 47% 47% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1426247
GSM967853U87-EV human glioblastoma xenograft - Control 23.1090547
GSM967854U87-EV human glioblastoma xenograft - Control 33.1108347
GSM967855U87-EV human glioblastoma xenograft - Control 43.0785948
GSM967856U87-EV human glioblastoma xenograft - Control 53.0366246
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1940547
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1157545
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1222848
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.461657
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0857347
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0902447
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0699247
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1011947
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1084347